Company intelligence / Profile preview
Bolden Therapeutics
Providence, Rhode Island, United Statesboldentherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Bolden Therapeutics has demonstrated proof-of-concept in proprietary mouse models showing increased neurogenesis and improved hippocampal-dependent memory by modulating a novel signaling pathway with exon-skipping antisense oligonucleotides. The company has received NIH/NIA SBIR/STTR grants to advance these candidates toward clinical development for Alzheimer’s disease and related CNS disorders. Human clinical trials have not yet begun.
- Therapeutic areas
- NeurologyCardiovascular
- Modalities
- Antisense oligonucleotide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Biogen (“Golden Ticket” incubator sponsorship at LabCentral/Kendall Square Cambridge MA lab space support)
Beyond the preview
Go deeper on Bolden Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bolden Therapeutics.